A Cost-Utility Analysis of the Risk Model-Guided Antiemetic Prophylaxis Versus Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer- A Net-Benefit Regression Approach

Nov 1, 2016, 00:00
10.1016/j.jval.2016.08.744
https://www.valueinhealthjournal.com/article/S1098-3015(16)33859-1/fulltext
Title : A Cost-Utility Analysis of the Risk Model-Guided Antiemetic Prophylaxis Versus Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer- A Net-Benefit Regression Approach
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33859-1&doi=10.1016/j.jval.2016.08.744
First page : A890
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 2742
Categories :
Tags :
Regions :
ViH Article Tags :